SI3538525T1 - 3-substituirane propionske kisline kot inhibitorji alfa v integrina - Google Patents

3-substituirane propionske kisline kot inhibitorji alfa v integrina

Info

Publication number
SI3538525T1
SI3538525T1 SI201731195T SI201731195T SI3538525T1 SI 3538525 T1 SI3538525 T1 SI 3538525T1 SI 201731195 T SI201731195 T SI 201731195T SI 201731195 T SI201731195 T SI 201731195T SI 3538525 T1 SI3538525 T1 SI 3538525T1
Authority
SI
Slovenia
Prior art keywords
alpha
propionic acids
integrin inhibitors
substituted propionic
substituted
Prior art date
Application number
SI201731195T
Other languages
English (en)
Slovenian (sl)
Inventor
Guohua Zhao
Pratik Devasthale
Xiang-Yang Ye
Kumaravel Selvakumar
Suresh Dhanusu
Palanikumar Balasubramanian
Leatte R. Guernon
Rita Civiello
Xiaojun Han
Michael F. Parker
Swanee E. Jacutin-Porte
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI3538525T1 publication Critical patent/SI3538525T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201731195T 2016-11-08 2017-11-07 3-substituirane propionske kisline kot inhibitorji alfa v integrina SI3538525T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418848P 2016-11-08 2016-11-08
PCT/US2017/060376 WO2018089353A1 (en) 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors
EP17801230.8A EP3538525B1 (en) 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors

Publications (1)

Publication Number Publication Date
SI3538525T1 true SI3538525T1 (sl) 2022-09-30

Family

ID=60409432

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731195T SI3538525T1 (sl) 2016-11-08 2017-11-07 3-substituirane propionske kisline kot inhibitorji alfa v integrina

Country Status (30)

Country Link
US (2) US10968219B2 (OSRAM)
EP (1) EP3538525B1 (OSRAM)
JP (1) JP7097358B2 (OSRAM)
KR (1) KR102505629B1 (OSRAM)
CN (1) CN110167935B (OSRAM)
AR (1) AR110153A1 (OSRAM)
AU (1) AU2017359023B2 (OSRAM)
CA (1) CA3042707A1 (OSRAM)
CL (1) CL2019001264A1 (OSRAM)
CO (1) CO2019005824A2 (OSRAM)
DK (1) DK3538525T3 (OSRAM)
EA (1) EA038164B1 (OSRAM)
ES (1) ES2925173T3 (OSRAM)
HR (1) HRP20220990T1 (OSRAM)
HU (1) HUE059708T2 (OSRAM)
IL (1) IL266473B (OSRAM)
LT (1) LT3538525T (OSRAM)
MA (1) MA46743A (OSRAM)
MX (1) MX380799B (OSRAM)
MY (1) MY199931A (OSRAM)
NZ (1) NZ754207A (OSRAM)
PE (1) PE20191647A1 (OSRAM)
PL (1) PL3538525T3 (OSRAM)
PT (1) PT3538525T (OSRAM)
RS (1) RS63483B1 (OSRAM)
SI (1) SI3538525T1 (OSRAM)
SM (1) SMT202200338T1 (OSRAM)
TW (1) TWI763733B (OSRAM)
WO (1) WO2018089353A1 (OSRAM)
ZA (1) ZA201903665B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
CA3042707A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as .alpha.v integrin inhibitors
CN110167934B (zh) * 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
JP7128811B2 (ja) * 2016-11-08 2022-08-31 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
US20220119383A1 (en) 2018-10-30 2022-04-21 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN109824495B (zh) * 2019-02-02 2022-12-09 盐城师范学院 一种新型偶联反应在制备碳-碳键结构化合物中的应用
CN119431230A (zh) 2019-08-14 2025-02-14 吉利德科学公司 用于抑制α4β7整合素的化合物
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
TW202513065A (zh) * 2023-09-21 2025-04-01 美商莫菲克醫療股份有限公司 抑制人類整合素α５β１

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
AU736026B2 (en) * 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
MXPA03006772A (es) 2001-01-29 2004-10-15 Dimensional Pharm Inc Indoles sustituidos y su uso como antogonistas de integrina.
BR0316875A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos de pirazol como derivados antagonistas receptores da integrina, sua composição farmacêutica e respectivo uso
WO2004058254A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
JP2013503834A (ja) 2009-09-04 2013-02-04 ビーエーエスエフ ソシエタス・ヨーロピア １−フェニルピラゾールの製造方法
RU2550821C2 (ru) 2009-10-29 2015-05-20 Сертрис Фармасьютикалз, Инк. Бициклические пиридины и аналоги в качестве модуляторов сиртуина
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
KR102647026B1 (ko) 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
JP2018515424A (ja) * 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗アルファｖベータ１インテグリン阻害剤及び使用方法
CA3042707A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as .alpha.v integrin inhibitors

Also Published As

Publication number Publication date
CN110167935A (zh) 2019-08-23
CN110167935B (zh) 2022-05-27
LT3538525T (lt) 2022-09-26
US11884661B2 (en) 2024-01-30
JP2019537594A (ja) 2019-12-26
EP3538525B1 (en) 2022-06-22
TW201823244A (zh) 2018-07-01
CL2019001264A1 (es) 2019-09-13
DK3538525T3 (da) 2022-08-29
HUE059708T2 (hu) 2022-12-28
EP3538525A1 (en) 2019-09-18
SMT202200338T1 (it) 2022-09-14
PE20191647A1 (es) 2019-11-07
PT3538525T (pt) 2022-08-16
RS63483B1 (sr) 2022-09-30
NZ754207A (en) 2025-09-26
IL266473A (en) 2019-07-31
ES2925173T3 (es) 2022-10-14
IL266473B (en) 2022-06-01
EA201991122A1 (ru) 2019-10-31
MY199931A (en) 2023-11-29
PL3538525T3 (pl) 2022-09-12
US20190263808A1 (en) 2019-08-29
AR110153A1 (es) 2019-02-27
CA3042707A1 (en) 2018-05-17
EA038164B1 (ru) 2021-07-16
AU2017359023B2 (en) 2021-12-09
HRP20220990T1 (hr) 2022-11-11
TWI763733B (zh) 2022-05-11
MX2019005244A (es) 2019-08-05
MX380799B (es) 2025-03-12
MA46743A (fr) 2019-09-18
CO2019005824A2 (es) 2019-06-11
KR102505629B1 (ko) 2023-03-02
JP7097358B2 (ja) 2022-07-07
US20210188847A1 (en) 2021-06-24
US10968219B2 (en) 2021-04-06
ZA201903665B (en) 2022-12-21
AU2017359023A1 (en) 2019-06-20
WO2018089353A1 (en) 2018-05-17
KR20190073554A (ko) 2019-06-26

Similar Documents

Publication Publication Date Title
ZA201903665B (en) 3-substituted propionic acids as alpha v integrin inhibitors
EP3193608A4 (en) Carm1 inhibitors and uses thereof
EP3200588A4 (en) Arginine methyltransferase inhibitors and uses thereof
EP3193611A4 (en) Mk2 inhibitors and uses thereof
EP3175023A4 (en) Systems and methods for determining nucleic acids
EP3134536A4 (en) Systems and methods for barcoding nucleic acids
IL267239A (en) New derivatives of phenylpropionic acid and their uses
EP3190682A4 (en) Power supply system and method
PL3218378T3 (pl) Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
EP3229899A4 (en) Methods and apparatus for electrosurgical illumination and sensing
EP3181085A4 (en) Tracking system and tracking method using same
EP3153561A4 (en) Composition for heat cycle system and heat cycle system
EP3153567A4 (en) Composition for heat cycle system and heat cycle system
EP3162276A4 (en) System and method for managing endoscopic scope
EP3102189A4 (en) Composition and method for aiding sleep
EP3238840A4 (en) Method for recycling used absorbent article
EP3166523A4 (en) Cryoablation method and system
EP3141930A4 (en) Distance-measurement device and method for powering distance-measurement device
EP3232039A4 (en) Method and device for energy-saving ship navigation
EP3155399A4 (en) Viscometer and methods for using the same
IL255054A0 (en) Tetrahydronephthyridinyl propionic acid derivatives and their uses
EP3387192A4 (en) APPARATUS FOR SANITARY PURPOSES AND WATER SUPPLY
EP3195129A4 (en) Application centric distributed storage system and method
EP3185880A4 (en) Improved peptidyl calcineurin inhibitors
EP3139918A4 (en) Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors